# Wenfeng Fang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/wenfeng-fang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,218 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 48 |
| i10-index | 159 |
| Last Known Institution | Sun Yat-sen University |
| OpenAlex ID | https://openalex.org/A5101713307 |
| ORCID iD | 0000-0002-6440-8246 |
| Works | 431 |

## Researcher papers

- [Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation](https://scholariq.org/papers/upregulation-of-pd-l1-by-egfr-activation-mediates-the-immune-escape-in-egfr/)
- [Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials](https://scholariq.org/papers/camrelizumab-shr-1210-alone-or-in-combination-with-gemcitabine-plus-cisplatin/)
- [Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/camrelizumab-versus-placebo-in-combination-with-gemcitabine-and-cisplatin-as/)
- [EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy](https://scholariq.org/papers/ebv-driven-lmp1-and-ifn-up-regulate-pd-l1-in-nasopharyngeal-carcinoma/)
- [KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma](https://scholariq.org/papers/kras-mutation-induced-upregulation-of-pd-l1-mediates-immune-escape-in-human-lung/)
- [The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs](https://scholariq.org/papers/the-association-between-pd-l1-and-egfr-status-and-the-prognostic-value-of-pd-l1/)
- [Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer](https://scholariq.org/papers/comprehensive-genomic-profiling-identifies-novel-genetic-predictors-of-response/)
- [Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes](https://scholariq.org/papers/genomic-analysis-of-nasopharyngeal-carcinoma-reveals-tme-based-subtypes/)
- [Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or/)
- [Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas](https://scholariq.org/papers/genetic-basis-of-pd-l1-overexpression-in-diffuse-large-b-cell-lymphomas/)
- [Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenes](https://scholariq.org/papers/rare-transformation-from-lung-adenocarcinoma-to-sarcomatoid-carcinoma-mediates/)
- [Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs](https://scholariq.org/papers/re-biopsy-confers-survival-benefit-through-directing-salvage-treatment-for/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Sun Yat-sen University](https://scholariq.org/institutions/sun-yat-sen-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.